Butylscopolammonium vs trihexyphenidyl
Mechanistic comparison of Butylscopolammonium Bromide Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal and trihexyphenidyl based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
4
Shared Targets
50%
Jaccard Similarity
44%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Evidence Comparison
Target Overlap
Butylscopolammonium and trihexyphenidyl share 4 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.500 means 50% of the combined target set is bound by both compounds. The IDF-weighted score of 0.444 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.